ArticleThe Journal of biological chemistry2025
The serine protease DPP9 and the redox sensor KEAP1 form a mutually inhibitory complex.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Proximity labeling reveals non-catalytic interactions between DPP9 and ubiquitin signaling complexes.Cellular and molecular life sciences : CMLS · 2026Article
- Targeting DPP9 attenuates podocyte injury by regulating NRF2 antioxidant signaling.Frontiers in pharmacology · 2026Article
- A fluorescent sensor for real-time monitoring of DPP8/9 reveals crucial roles in immunity and cancer.Life science alliance · 2025Article
- The multifunctional regulatory post-proline protease dipeptidyl peptidase 9 and its inhibitors: new opportunities for therapeutics.Cellular and molecular life sciences : CMLS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Synthetic inhibitors of the serine protease DPP9 activate the related NLRP1 and CARD8 inflammasomes and stimulate powerful innate immune responses. Thus, it seems plausible that a biomolecule similarly inhibits DPP9 and triggers inflammasome activation during infection, but one has not yet been discovered. Here, we wanted to identify and characterize DPP9-binding proteins to potentially uncover physiologically relevant mechanisms that control DPP9's activity. Notably, we found that the redox sensor protein KEAP1 binds to DPP9 in an inactive conformation and stabilizes this non-native fold. At the same time, this inactive form of DPP9 reciprocally inhibits the ability of KEAP1 to bind to and degrade the transcription factor NRF2, thereby inducing an antioxidant response. Although we discovered several experimental conditions, for example new protein expression and chemical denaturation, that force DPP9 out of its folded dimeric state and into a KEAP1-binding state, the key danger-related stimulus that causes this critical DPP9 conformational change is not yet known. Regardless, our data now reveal that an endogenous DPP9 inhibition mechanism does in fact exist, and moreover that DPP9, like the other NLRP1 regulator thioredoxin-1, is directly coupled to the intracellular redox potential. Overall, we expect this work will provide the foundation to discover additional biomolecules that regulate DPP9's activity, the DPP9-KEAP1 interaction, the intracellular redox environment, and the NLRP1 and CARD8 inflammasomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.